New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab
{{output}}
The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years and has paved the path for other subspecialties. Whi... ...
